Education
About Us
Working with TipRanks
Follow Us
Chugai Pharmaceutical Co Ltd (JP:4519)
:4519
Obinutuzumab, Alps12
Extensive Stage Small Cell Lung Cancer
Phase I
Not Yet Recruiting
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Jul 30, 2025
―
Aube00
Solid Tumors
Phase I
Recruiting
Study of AUBE00 in Patients With Solid Tumors
May 11, 2025
―
Afimkibart
Moderately To Severely Active Crohns Disease
Phase III
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Feb 06, 2025
―
Afimkibart
Moderately To Severely Active Crohns Disease
Phase III
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Feb 06, 2025
―
Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Divarasib
Non-small Cell Lung Cancer, Kras G12c Lung Cancer
Phase III
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Jan 20, 2025
―
Ray121
Bullous Pemphigoid (Bp), Immune Thrombocytopenia (Itp), Antiphospholipid Syndrome (Aps), Behçet's Syndrome (Bs), Dermatomyositis (Dm), Immune-Mediated Necrotizing Myopathy (Imnm)
Phase I
Enrolling By Invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Nov 27, 2024
―
Afimkibart
Moderately To Severely Active Ulcerative Colitis
Phase III
Recruiting
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Sep 06, 2024
―
Sotorasib, Adagrasib, Divarasib
Non-small Cell Lung Cancer, Kras G12c Lung Cancer
Phase III
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Jul 05, 2024
―
Ray121
Bullous Pemphigoid (Bp), Immune Thrombocytopenia (Itp), Antiphospholipid Syndrome (Aps), Behçet's Syndrome (Bs), Dermatomyositis (Dm), Immune-Mediated Necrotizing Myopathy (Imnm)
Phase I
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Apr 04, 2024
―
Bevacizumab, Atezolizumab, Tiragolumab
Hepatocellular Carcinoma
Phase III
Active Not Recruiting
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
May 23, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Chugai Pharmaceutical Co Ltd (4519) have in its pipeline
4519 is currently developing the following drugs: Obinutuzumab, Alps12, Aube00, Afimkibart. These drug candidates are in various stages of clinical development as the company works toward FDA approval.